Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment
In the real-world setting, sonidegib-treated patients remained on treatment longer than vismodegib-treated patients and were less likely to experience pharmacologically relevant clinical conditions.
Authors
- Zeynep Eroglu (ORCID: https://orcid.org/0000-0002-2307-7030)
- Lynn Huynh (ORCID: https://orcid.org/0000-0003-3110-6775)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Nicholas Squittieri
- Victoria Barghout (ORCID: https://orcid.org/0000-0003-4234-1527)
- Enrico Zanardo (ORCID: https://orcid.org/0009-0009-7011-1180)
- Deepshekhar Gupta (ORCID: https://orcid.org/0000-0002-3695-3546)
- Darrell S. Rigel (ORCID: https://orcid.org/0000-0002-4005-7031)
- Kunal Patel (ORCID: https://orcid.org/0000-0002-9854-9178)
- Mihran Yenikomshian
- Thomas J. Ferro
Institutions
- Moffitt Cancer Center (US)
- Menlo School (US)
- Sun Pharma (United States) (US)
- New York University (US)
- Atlantic Health System (US)
- Analysis Group (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1007/s13555-025-01621-w
- Primary Topic
- Hedgehog Signaling Pathway Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sun Pharma